2019
DOI: 10.1111/bjd.18133
|View full text |Cite
|
Sign up to set email alerts
|

Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 8 publications
0
11
0
Order By: Relevance
“…Commercial assays to detect MSAAs are now in widespread use worldwide. Limited validation, particularly for rarer autoantibodies, has been a growing concern among the myositis community [ 6 , 12 , 13 ]. Previous studies in this area have been small, with low numbers of sera containing individual MSAA specificities [ 6 , 14 , 15 ].…”
Section: Discussionmentioning
confidence: 99%
“…Commercial assays to detect MSAAs are now in widespread use worldwide. Limited validation, particularly for rarer autoantibodies, has been a growing concern among the myositis community [ 6 , 12 , 13 ]. Previous studies in this area have been small, with low numbers of sera containing individual MSAA specificities [ 6 , 14 , 15 ].…”
Section: Discussionmentioning
confidence: 99%
“…There is however, a need for better standardization of measurement of DM autoantibodies. A recent study showed just 14% of patients with DM had MSAs and 21% had MSAs when testing was done in commercial labs [170] . Hopefully the detection rate of autoantibodies will improve with time and allow better correlation with disease phenotype.…”
Section: Dm Rashes and The Antisynthetase Syndromementioning
confidence: 99%
“…Statements released by the Association of Professors of Dermatology (APD) in April and June 2020 addressed student concerns and suggested modifications to the application process (Table I). 1,2 To complement these statements, the Dermatology Interest Group Association (DIGA) hosted a webinar for dermatology residency hopefuls. Similar webinars have been held by national specialty organizations in orthopedic surgery, ophthalmology, and emergency medicine.…”
Section: A National Webinar For Dermatology Applicants During the Covmentioning
confidence: 99%
“…To the Editor: Laboratory panels for myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are increasingly being used in the diagnosis and prognostication of dermatomyositis (DM). 1,2 However, many commercial panels used in clinical settings have limited validation compared to other methodologies. 3 To understand the accuracy of commercial myositis panels in the clinical setting, we performed a cross-sectional analysis of patients with DM, comparing commercially available myositis panels to panels performed in the research setting.…”
mentioning
confidence: 99%